Erythroderma after autologous bone marrow transplantation modified by administration of cyclosporine and interferon gamma for breast cancer

Thomas D. Horn, Viki Altomonte, Georgia Boyce Vogelsang, M. John Kennedy

Research output: Contribution to journalArticle

Abstract

Background: Allogeneic graft-versus-host disease is associated with decreased rates of tumor relapse. The addition of interferon gamma to cyclosporine, given to induce graft-versus-host disease after autologous bone marrow transplantation, increases the extent of the cutaneous eruption. Objective: Our purpose was to describe the clinical and histologic cutaneous changes in 10 patients with breast cancer who received interferon gamma to potentiate graft-versus-host disease after autologous bone marrow transplantation modified by cyclosporine. Methods: Ten women receiving autologous bone marrow transplantation modified by the administration of cyclosporine and interferon gamma were observed clinically with sequential biopsy of the skin weekly and at the time of cutaneous eruptions. Results: Erythroderma (stage 3) developed in five women after the first or second administration of interferon gamma. At least one skin biopsy specimen from 7 of the 10 women showed grade 2 changes of graft-versus-host reaction, including all patients with erythroderma. Epidermal intercellular edema was prominent in these specimens with expression of keratinocyte HLA-DR and intercellular adhesion molecule 1. Induction of keratinocyte HLA-DR and intercellular adhesion molecule 1 expression was not observed in specimens from normal skin during administration of interferon gamma. Conclusion: This protocol causes a more widely distributed cutaneous eruption, including erythroderma (50%), than autologous bone marrow transplantation and cyclosporine administration alone (3%). Whether it will affect survival is unknown.

Original languageEnglish (US)
Pages (from-to)413-417
Number of pages5
JournalJournal of the American Academy of Dermatology
Volume34
Issue number3
DOIs
StatePublished - Mar 1996

Fingerprint

Exfoliative Dermatitis
Autologous Transplantation
Bone Marrow Transplantation
Cyclosporine
Interferon-gamma
Breast Neoplasms
Skin
Graft vs Host Disease
HLA-DR Antigens
Intercellular Adhesion Molecule-1
Keratinocytes
Biopsy
Edema
Transplants
Recurrence
Survival

ASJC Scopus subject areas

  • Dermatology

Cite this

Erythroderma after autologous bone marrow transplantation modified by administration of cyclosporine and interferon gamma for breast cancer. / Horn, Thomas D.; Altomonte, Viki; Vogelsang, Georgia Boyce; Kennedy, M. John.

In: Journal of the American Academy of Dermatology, Vol. 34, No. 3, 03.1996, p. 413-417.

Research output: Contribution to journalArticle

@article{f9884f2f13984b52968be5b4d553f7a6,
title = "Erythroderma after autologous bone marrow transplantation modified by administration of cyclosporine and interferon gamma for breast cancer",
abstract = "Background: Allogeneic graft-versus-host disease is associated with decreased rates of tumor relapse. The addition of interferon gamma to cyclosporine, given to induce graft-versus-host disease after autologous bone marrow transplantation, increases the extent of the cutaneous eruption. Objective: Our purpose was to describe the clinical and histologic cutaneous changes in 10 patients with breast cancer who received interferon gamma to potentiate graft-versus-host disease after autologous bone marrow transplantation modified by cyclosporine. Methods: Ten women receiving autologous bone marrow transplantation modified by the administration of cyclosporine and interferon gamma were observed clinically with sequential biopsy of the skin weekly and at the time of cutaneous eruptions. Results: Erythroderma (stage 3) developed in five women after the first or second administration of interferon gamma. At least one skin biopsy specimen from 7 of the 10 women showed grade 2 changes of graft-versus-host reaction, including all patients with erythroderma. Epidermal intercellular edema was prominent in these specimens with expression of keratinocyte HLA-DR and intercellular adhesion molecule 1. Induction of keratinocyte HLA-DR and intercellular adhesion molecule 1 expression was not observed in specimens from normal skin during administration of interferon gamma. Conclusion: This protocol causes a more widely distributed cutaneous eruption, including erythroderma (50{\%}), than autologous bone marrow transplantation and cyclosporine administration alone (3{\%}). Whether it will affect survival is unknown.",
author = "Horn, {Thomas D.} and Viki Altomonte and Vogelsang, {Georgia Boyce} and Kennedy, {M. John}",
year = "1996",
month = "3",
doi = "10.1016/S0190-9622(96)90431-4",
language = "English (US)",
volume = "34",
pages = "413--417",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Erythroderma after autologous bone marrow transplantation modified by administration of cyclosporine and interferon gamma for breast cancer

AU - Horn, Thomas D.

AU - Altomonte, Viki

AU - Vogelsang, Georgia Boyce

AU - Kennedy, M. John

PY - 1996/3

Y1 - 1996/3

N2 - Background: Allogeneic graft-versus-host disease is associated with decreased rates of tumor relapse. The addition of interferon gamma to cyclosporine, given to induce graft-versus-host disease after autologous bone marrow transplantation, increases the extent of the cutaneous eruption. Objective: Our purpose was to describe the clinical and histologic cutaneous changes in 10 patients with breast cancer who received interferon gamma to potentiate graft-versus-host disease after autologous bone marrow transplantation modified by cyclosporine. Methods: Ten women receiving autologous bone marrow transplantation modified by the administration of cyclosporine and interferon gamma were observed clinically with sequential biopsy of the skin weekly and at the time of cutaneous eruptions. Results: Erythroderma (stage 3) developed in five women after the first or second administration of interferon gamma. At least one skin biopsy specimen from 7 of the 10 women showed grade 2 changes of graft-versus-host reaction, including all patients with erythroderma. Epidermal intercellular edema was prominent in these specimens with expression of keratinocyte HLA-DR and intercellular adhesion molecule 1. Induction of keratinocyte HLA-DR and intercellular adhesion molecule 1 expression was not observed in specimens from normal skin during administration of interferon gamma. Conclusion: This protocol causes a more widely distributed cutaneous eruption, including erythroderma (50%), than autologous bone marrow transplantation and cyclosporine administration alone (3%). Whether it will affect survival is unknown.

AB - Background: Allogeneic graft-versus-host disease is associated with decreased rates of tumor relapse. The addition of interferon gamma to cyclosporine, given to induce graft-versus-host disease after autologous bone marrow transplantation, increases the extent of the cutaneous eruption. Objective: Our purpose was to describe the clinical and histologic cutaneous changes in 10 patients with breast cancer who received interferon gamma to potentiate graft-versus-host disease after autologous bone marrow transplantation modified by cyclosporine. Methods: Ten women receiving autologous bone marrow transplantation modified by the administration of cyclosporine and interferon gamma were observed clinically with sequential biopsy of the skin weekly and at the time of cutaneous eruptions. Results: Erythroderma (stage 3) developed in five women after the first or second administration of interferon gamma. At least one skin biopsy specimen from 7 of the 10 women showed grade 2 changes of graft-versus-host reaction, including all patients with erythroderma. Epidermal intercellular edema was prominent in these specimens with expression of keratinocyte HLA-DR and intercellular adhesion molecule 1. Induction of keratinocyte HLA-DR and intercellular adhesion molecule 1 expression was not observed in specimens from normal skin during administration of interferon gamma. Conclusion: This protocol causes a more widely distributed cutaneous eruption, including erythroderma (50%), than autologous bone marrow transplantation and cyclosporine administration alone (3%). Whether it will affect survival is unknown.

UR - http://www.scopus.com/inward/record.url?scp=0030002911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030002911&partnerID=8YFLogxK

U2 - 10.1016/S0190-9622(96)90431-4

DO - 10.1016/S0190-9622(96)90431-4

M3 - Article

C2 - 8609251

AN - SCOPUS:0030002911

VL - 34

SP - 413

EP - 417

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 3

ER -